Ticker

TORONTO and HAIFA, Israel, April 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotechnology company developing exosome-based therapies for central nervous system injuries, is pleased to announce that it received first place in the Healthcare category at the BOLD Awards VII Gala held in Barcelona on March 27, 2026 and provides corporate…

Boundless Bio offers a highly asymmetric risk/reward profile, trading at a $25M valuation with $107.6M in cash and a runway into 2H 2028. BBI-940, BOLD's first direct ecDNA-targeting asset, is entering clinical trials with promising preclinical efficacy, high selectivity, and a rational mechanism of action. Previous clinical failures (BBI-825, BBI-335) targeted indirect vulnerabilities, but BBI-940 directly…

SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced an upcoming poster presentation on their oral Kinesin degrader program at the American Association for Cancer Research (AACR) Annual…

Consulting Agreement with Former Bayer Principal Scientist, BOLD Awards Healthcare Finalist Status, and Private Placement Closing Consulting Agreement with Former Bayer Principal Scientist, BOLD Awards Healthcare Finalist Status, and Private Placement Closing

Dot's brings its iconic buttery-rich pretzels and bold Original seasoning to Snack Mix! HERSHEY, Pa.